Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.

Espay AJ, Pagan FL, Walter BL, Morgan JC, Elmer LW, Waters CH, Agarwal P, Dhall R, Ondo WG, Klos KJ, Silver DE.

Neurol Clin Pract. 2017 Feb;7(1):86-93. doi: 10.1212/CPJ.0000000000000316. Review.

2.

Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis.

Chan RB, Perotte AJ, Zhou B, Liong C, Shorr EJ, Marder KS, Kang UJ, Waters CH, Levy OA, Xu Y, Shim HB, Pe'er I, Di Paolo G, Alcalay RN.

PLoS One. 2017 Feb 17;12(2):e0172348. doi: 10.1371/journal.pone.0172348. eCollection 2017.

3.

SCARB2 variants and glucocerebrosidase activity in Parkinson's disease.

Alcalay RN, Levy OA, Wolf P, Oliva P, Zhang XK, Waters CH, Fahn S, Kang U, Liong C, Ford B, Mazzoni P, Kuo S, Johnson A, Xiong L, Rouleau GA, Chung W, Marder KS, Gan-Or Z.

NPJ Parkinsons Dis. 2016;2. pii: 16004. Epub 2016 Mar 10.

4.

Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.

Waters CH, Nausieda P, Dzyak L, Spiegel J, Rudzinska M, Silver DE, Tsurkalenko ES, Kell S, Hsu A, Khanna S, Gupta S.

CNS Drugs. 2015 Apr;29(4):341-50. doi: 10.1007/s40263-015-0242-2.

5.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
6.

Cognitive and motor function in long-duration PARKIN-associated Parkinson disease.

Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella CL, Nance MA, Bressman SB, Scott WK, Tanner CM, Mickel SF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak KE, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Payami H, Molho E, Factor SA, Nutt JG, Serrano C, Arroyo M, Ottman R, Pauciulo MW, Nichols WC, Clark LN, Marder KS.

JAMA Neurol. 2014 Jan;71(1):62-7. doi: 10.1001/jamaneurol.2013.4498.

7.

Knowledge of and interest in genetic results among Parkinson disease patients and caregivers.

Sakanaka K, Waters CH, Levy OA, Louis ED, Chung WK, Marder KS, Alcalay RN.

J Genet Couns. 2014 Feb;23(1):114-20. doi: 10.1007/s10897-013-9618-y. Epub 2013 Jun 9.

8.

Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease.

Wright BA, Waters CH.

Expert Rev Neurother. 2013 Jun;13(6):719-29. doi: 10.1586/ern.13.47. Review.

PMID:
23739008
9.

Applause sign in clinically overlapping diseases: a case of TDP-43 proteinopathy.

Arkadir D, Greene PE, Waters CH, Moskowitz CB, Sharp ME.

Parkinsonism Relat Disord. 2013 Aug;19(8):774-5. doi: 10.1016/j.parkreldis.2013.04.016. Epub 2013 May 13. No abstract available.

PMID:
23680421
10.

Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease.

Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Clark LN, Marder KS, Caccappolo E.

J Clin Exp Neuropsychol. 2010 Aug;32(7):775-9. doi: 10.1080/13803390903521018. Epub 2010 Feb 24.

11.

Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.

Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder KS.

Arch Neurol. 2009 Dec;66(12):1517-22. doi: 10.1001/archneurol.2009.267.

12.

Current strategies in the treatment of Parkinson's disease and a personalized approach to management.

Diaz NL, Waters CH.

Expert Rev Neurother. 2009 Dec;9(12):1781-9. doi: 10.1586/ern.09.117. Review.

PMID:
19951137
13.

Eye movement abnormalities in a case of X-linked dystonia-Parkinsonism (lubag).

Esmaili DD, Shubin RA, Waters CH, Sadun AA.

J Neuroophthalmol. 2004 Jun;24(2):188-9. No abstract available.

PMID:
15179077
14.

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.

Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM; Zydis Selegiline Study Group.

Mov Disord. 2004 Apr;19(4):426-32.

PMID:
15077240
15.

Corticobasal Degeneration.

Piboolnurak P, Waters CH.

Curr Treat Options Neurol. 2003 Mar;5(2):161-168.

PMID:
12628064
16.

Treatment of advanced stage patients with Parkinson's disease.

Waters CH.

Parkinsonism Relat Disord. 2002 Oct;9(1):15-21. Review.

PMID:
12217618
17.

PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study.

DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF, Maher NE, Wilk JB, Sullivan KM, Slater KM, Saint-Hilaire MH, Feldman RG, Suchowersky O, Lafontaine AL, Labelle N, Growdon JH, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Reider CR, Stacy M, MacDonald ME, Gusella JF, Myers RH.

Am J Hum Genet. 2002 May;70(5):1089-95. Epub 2002 Mar 27.

18.

Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study.

Maher NE, Golbe LI, Lazzarini AM, Mark MH, Currie LJ, Wooten GF, Saint-Hilaire M, Wilk JB, Volcjak J, Maher JE, Feldman RG, Guttman M, Lew M, Waters CH, Schuman S, Suchowersky O, Lafontaine AL, Labelle N, Vieregge P, Pramstaller PP, Klein C, Hubble J, Reider C, Growdon J, Watts R, Montgomery E, Baker K, Singer C, Stacy M, Myers RH.

Neurology. 2002 Jan 8;58(1):79-84. Erratum in: Neurology. 2002 Apr 9;58(7):1136.

PMID:
11781409
19.

Genome-wide scan for Parkinson's disease: the GenePD Study.

DeStefano AL, Golbe LI, Mark MH, Lazzarini AM, Maher NE, Saint-Hilaire M, Feldman RG, Guttman M, Watts RL, Suchowersky O, Lafontaine AL, Labelle N, Lew MF, Waters CH, Growdon JH, Singer C, Currie LJ, Wooten GF, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Stacy M, Montgomery E, MacDonald ME, Gusella JF, Myers RH.

Neurology. 2001 Sep 25;57(6):1124-6.

PMID:
11571351
20.

Advances in managing Parkinson's disease.

Waters CH.

Hosp Pract (1995). 2001 Jun 15;36(6):27-32, 41.

PMID:
11419534
21.

Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.

Hutton JT, Metman LV, Chase TN, Juncos JL, Koller WC, Pahwa R, LeWitt PA, Samii A, Tsui JK, Calne DB, Waters CH, Calabrese VP, Bennett JP, Barrett R, Morris JL.

Mov Disord. 2001 May;16(3):459-63.

PMID:
11391739
22.

The long-term safety and efficacy of pramipexole in advanced Parkinson's disease.

Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, Shulman LM, Glassman PM, Beck B, Paume D, Doyle C.

Parkinsonism Relat Disord. 2001 Apr;7(2):115-120.

PMID:
11248592
23.

Impaired perception of vocal emotions in Parkinson's disease: influence of speech time processing and executive functioning.

Breitenstein C, Van Lancker D, Daum I, Waters CH.

Brain Cogn. 2001 Mar;45(2):277-314.

PMID:
11237372
24.

Essential Tremor.

Lambert D, Waters CH.

Curr Treat Options Neurol. 1999 Mar;1(1):6-13.

PMID:
11096690
25.

Sexual dysfunction in Parkinson's disease.

Lambert D, Waters CH.

Clin Neurosci. 1998;5(2):73-7. Review.

PMID:
10785831
26.

Comparative tolerability of the newer generation antiparkinsonian agents.

Lambert D, Waters CH.

Drugs Aging. 2000 Jan;16(1):55-65. Review.

PMID:
10733264
27.

A 32-year-old man with progressive spasticity and parkinsonism.

Frucht S, Fahn S, Shannon KM, Waters CH.

Mov Disord. 1999 Mar;14(2):350-7. No abstract available.

PMID:
10091633
28.

A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group.

Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, Hurtig H, Yahr M.

Neurology. 1998 Oct;51(4):1057-62. Erratum in: Neurology 1999 Jan 15;52(2):435.

PMID:
9781529
29.

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.

Waters CH, Kurth M, Bailey P, Shulman LM, LeWitt P, Dorflinger E, Deptula D, Pedder S.

Neurology. 1998 May;50(5 Suppl 5):S39-45.

PMID:
9591521
30.

Sexuality in women with Parkinson's disease.

Welsh M, Hung L, Waters CH.

Mov Disord. 1997 Nov;12(6):923-7.

PMID:
9399216
31.

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group.

Waters CH, Kurth M, Bailey P, Shulman LM, LeWitt P, Dorflinger E, Deptula D, Pedder S.

Neurology. 1997 Sep;49(3):665-71.

PMID:
9305320
32.

Managing the late complications of Parkinson's disease.

Waters CH.

Neurology. 1997 Jul;49(1 Suppl 1):S49-57. Review.

PMID:
9222274
33.

Basal ganglia calcification after mumps encephalitis.

Abrey LE, Waters CH.

Mov Disord. 1996 Nov;11(6):755-6. No abstract available.

PMID:
8914112
34.

Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.

Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI, Stern MB, Hiner BC, Lieberman A, Pfeiffer RF, Rodnitzky RL, Waters CH, Muenter MD, Adler CH, Morris JL.

Neurology. 1996 Apr;46(4):1062-5.

PMID:
8780092
35.

Ventroposterior medial pallidotomy in patients with advanced Parkinson's disease.

Sutton JP, Couldwell W, Lew MF, Mallory L, Grafton S, DeGiorgio C, Welsh M, Apuzzo ML, Ahmadi J, Waters CH.

Neurosurgery. 1995 Jun;36(6):1112-6; discussion 1116-7.

PMID:
7643989
36.

The frequently low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalities.

Carmel R, Gott PS, Waters CH, Cairo K, Green R, Bondareff W, DeGiorgio CM, Cummings JL, Jacobsen DW, Buckwalter G, et al.

Eur J Haematol. 1995 Apr;54(4):245-53.

PMID:
7789470
37.

Fluoxetine and selegiline--lack of significant interaction.

Waters CH.

Can J Neurol Sci. 1994 Aug;21(3):259-61.

PMID:
8000982
38.

Adductor laryngeal breathing dystonia in a patient with lubag (X-linked dystonia-Parkinsonism syndrome).

Lew MF, Shindo M, Moskowitz CB, Wilhelmsen KC, Fahn S, Waters CH.

Mov Disord. 1994 May;9(3):318-20.

PMID:
8041372
39.

Outcomes of pregnancy associated with antiepileptic drugs.

Waters CH, Belai Y, Gott PS, Shen P, De Giorgio CM.

Arch Neurol. 1994 Mar;51(3):250-3.

PMID:
8129635
40.

Autosomal dominant Lewy body parkinsonism in a four-generation family.

Waters CH, Miller CA.

Ann Neurol. 1994 Jan;35(1):59-64.

PMID:
8285594
41.

Phenotypic expression of X-linked dystonia-parkinsonism (lubag) in two women.

Waters CH, Takahashi H, Wilhelmsen KC, Shubin R, Snow BJ, Nygaard TG, Moskowitz CB, Fahn S, Calne DB.

Neurology. 1993 Aug;43(8):1555-8.

PMID:
8351010
42.

Neuropathology of lubag (x-linked dystonia parkinsonism).

Waters CH, Faust PL, Powers J, Vinters H, Moskowitz C, Nygaard T, Hunt AL, Fahn S.

Mov Disord. 1993 Jul;8(3):387-90.

PMID:
8341310
43.

Clozapine treatment of parkinsonism with psychosis.

Lew MF, Waters CH.

J Am Geriatr Soc. 1993 Jun;41(6):669-71. No abstract available.

PMID:
8505467
44.

Dead birds and dead fish.

Waters CH Jr.

J Calif Dent Assoc. 1992 Oct;20(10):8. No abstract available.

PMID:
1283874
45.

Long-term follow-up of adrenal medullary transplantation for Parkinson's disease.

Waters CH, Apuzzo ML, Neal JH, Weiner LP.

J Geriatr Psychiatry Neurol. 1992 Jan-Mar;5(1):35-9.

PMID:
1571072
46.

Side effects of selegiline (Eldepryl).

Waters CH.

J Geriatr Psychiatry Neurol. 1992 Jan-Mar;5(1):31-4.

PMID:
1571071
47.

Selegiline (Eldepryl) for Parkinson's disease.

Waters CH.

West J Med. 1991 Jul;155(1):68-9. No abstract available.

48.

Utilization of unilateral and bilateral stereotactically placed adrenomedullary-striatal autografts in parkinsonian humans: rationale, techniques, and observations.

Apuzzo ML, Neal JH, Waters CH, Appley AJ, Boyd SD, Couldwell WT, Wheelock VH, Weiner LP.

Neurosurgery. 1990 May;26(5):746-57.

PMID:
2191238
49.

Treatment of non-unions of fractures of the tibial diaphysis by posterolateral cortical cancellous bone-grafting.

Reckling FW, Waters CH 3rd.

J Bone Joint Surg Am. 1980 Sep;62(6):936-41.

PMID:
7000787
50.

Bilateral myxomas of the heart.

FRANKENFELD RH, WATERS CH, STEINER RC.

Ann Intern Med. 1960 Oct;53:827-38. No abstract available.

PMID:
13701419

Supplemental Content

Loading ...
Support Center